8 Feb 2022
ANSTO is in the process of constructing the SyMo facility which is intended to utilise SYNROC technology to immobilise waste from ANSTO’s Mo-99 production processes.
29 Oct 2021
On 29 June 2018, the ARPANSA CEO issued a Direction to ANSTO to initiate an independent safety review following a series of events with safety implications at the ANSTO Health (now Health Products) facility. ARPANSA has been monitoring progress against the implementation plan and is generally satisfied with the actions taken to date.
Clipboard icon with checkbox
31 Mar 2020
On 27 March 2020, the CEO of ARPANSA, Dr Carl-Magnus Larsson, removed a licence condition from the ANSTO Nuclear Medicine (ANM) facility, allowing it to return to routine operation.
Clipboard icon with checkbox
6 Dec 2019
In June 2018, ARPANSA issued a direction to its licence holder, the Australian Nuclear Science and Technology Organisation (ANSTO), to initiate an independent review of its approach to occupational radiation safety at its nuclear medicine facility operated by ANSTO Health, now known as Health Products.
26 Jun 2019
On Friday 21 June 2019, ARPANSA was notified of a radiation contamination event at the Australian Nuclear Science and Technology Organisation (ANSTO) Nuclear Medicine (ANM) production facility in Lucas Heights, New South Wales.

Access to information FOI disclosure log Information public scheme